BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18381)

  • 1. Qualitative changes in fibrinogen following exposure to agents used for preparation of fibrin monomers.
    Brosstad F; Godal HC
    Haemostasis; 1977; 6(3):149-56. PubMed ID: 18381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clottability and cross-linking reactivity of fibrin(ogen) following differential release of fibrinopeptides A and B.
    Furlan M; Seelich T; Beck EA
    Thromb Haemost; 1976 Dec; 36(3):582-92. PubMed ID: 14415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of fibrin monomers from human fibrinogen in urea, using soluble or insolubilized thrombin.
    Brosstad F; Godal HC; Kierulf P
    Haemostasis; 1977; 6(4):225-35. PubMed ID: 914081
    [No Abstract]   [Full Text] [Related]  

  • 4. The conversion of fibrinogen to fibrin. XIII. Dissolution of fibrin and inhibition of clotting by various neutral salts.
    SHULMAN S; KATZ S; FERRY JD
    J Gen Physiol; 1953 Jul; 36(6):759-66. PubMed ID: 13069679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of soluble fibrin monomer complexes by adsorption on immobilized fibrinogen.
    Stemberger AW; Hörmann H
    Thromb Haemost; 1978 Jun; 39(3):574-81. PubMed ID: 568324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity of fibrinogen crosslinking sites in the absence of thrombin.
    Seelich T; Furlan M; Beck EA
    Thromb Haemost; 1976 Jun; 35(3):620-7. PubMed ID: 10637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional evaluation of an inherited abnormal fibrinogen: fibrinogen "Baltimore".
    Beck EA; Shainoff JR; Vogel A; Jackson DP
    J Clin Invest; 1971 Sep; 50(9):1874-84. PubMed ID: 5564395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin.
    Merskey C; Johnson AJ; Lalezari P
    J Clin Invest; 1972 Apr; 51(4):903-11. PubMed ID: 5014617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin clotting time--a more sensitive indicator of denatured fibrinogen than clottability.
    Ly B; Godal HC; Kierulf P
    Haemostasis; 1972; 1(1):44-51. PubMed ID: 4668763
    [No Abstract]   [Full Text] [Related]  

  • 11. Soluble fibrin monomer complexes demonstrated by agarose gel filtration and by adsorption on insolubilized fibrinogen: a comparative study.
    von Hugo R; Stemberger A; Graeff H
    Thromb Diath Haemorrh; 1975 Sep; 34(1):216-22. PubMed ID: 1188711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAPAIN-INDUCED POLYMERIZATION OF FIBRINOGEN.
    LORAND L; KONISHI K
    Biochemistry; 1964 Jul; 3():915-9. PubMed ID: 14214078
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanisms involved in fibrin formation.
    BOYLES PW; FERGUSON JH; MUEHLKE PH
    J Gen Physiol; 1951 May; 34(5):493-513. PubMed ID: 14832433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solubility fo fibrin clots in monochloroacetic acid. A reflection of serum pepsinogen levels.
    Ikemori R; Gruhl M; Shrivastava S; Shanberge JN
    Am J Clin Pathol; 1975 Jan; 63(1):49-56. PubMed ID: 234201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and purification of fibrinogen/fibrin degradation products by chromatography on protamine-agarose.
    Dempfle CE; Heene DL
    Thromb Res; 1987 Oct; 48(2):223-32. PubMed ID: 3424289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
    Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
    J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electron microscopic study of the depolymerization process on unstabilized fibrin as affected by urea or monochloracetic acid].
    Ul'ianov AM; Zhitnikova ES
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (8):59-63. PubMed ID: 6226322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ioxaglate--an ionic low osmolar contrast medium--on fibrin polymerization in vitro.
    Brass O; Belleville J; Sabattier V; Corot C
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):689-97. PubMed ID: 8292718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.